← United States · Coverage record
US · SEC FORM 4
Ascendis Pharma A/S
ASND · Nasdaq · CIK 0001612042 · Healthcare · Biotechnology
INSIDER SIGNAL
5 qualifying P purchase groups
in the current 180-day scoring window
13 Form 4 transaction lines observed in the same window
3 sales · 1 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
—
Purchase breadth & concentration
Roles in the peak window: Director, EVP & Chief Financial Officer. Concentration uses priced qualifying P lines only and does not change the saved score.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-08-14 · BIENAIME JEAN JACQUES.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.
Price performance
- 1M
- -14.6%
- 3M
- -17.7%
- 6M
- -7.9%
- 12M
- +6.1%
Volatility & liquidity
- Volatility
- 39.7%
- Beta
- —
- Avg daily value
- USD 148.6M
Valuation
- Market cap
- —
- P/E
- —
Fundamentals
- Profit margin
- —
- ROE
- —
- Industry
- Biotechnology
Market data
Price data up to: 2026-10-08 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · Status: PASS
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 3,484,067
- Previous report
- 3,961,960
- Avg daily volume
- 937,174
- Days to cover
- 3.7
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-08-14 | BIENAIME JEAN JACQUES | Purchase (P) | Ordinary Shares | 2,000 | USD 246.33 | USD 492,654 | SEC filing ↗ |
| 2026-06-02 | SMITH SCOTT THOMAS | Purchase (P) | Ordinary Shares | 100 | USD 219.00 | USD 21,900 | SEC filing ↗ |
| 2026-05-29 | SMITH SCOTT THOMAS | Purchase (P) | Ordinary Shares | 250 | USD 223.32 | USD 55,830 | SEC filing ↗ |
| 2026-05-29 | BIENAIME JEAN JACQUES | Purchase (P) | Ordinary Shares | 500 | USD 223.12 | USD 111,562 | SEC filing ↗ |
| 2026-05-26 | BIENAIME JEAN JACQUES | Purchase (P) | Ordinary Shares | 400 | USD 237.81 | USD 95,122 | SEC filing ↗ |
Form 4 evidence
13 transaction lines in the latest 365-day window; 13 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Bodenhoff Mads | Sale (S) | Ordinary Shares | 3,000 | USD 270.19 | USD 810,570 | SEC filing ↗ |
| 2026-09-08 | Bodenhoff Mads | Option exercise / conversion (M) | Ordinary Shares | 3,000 | USD 110.00 | USD 330,000 | SEC filing ↗ |
| 2026-09-02 | HOLTUG LARS | Sale (S) | Ordinary Shares | 236 | USD 264.13 | USD 62,335 | SEC filing ↗ |
Show recent Form 4 evidence (9 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Bodenhoff Mads | Sale (S) | Ordinary Shares | 3,000 | USD 270.19 | USD 810,570 | SEC filing ↗ |
| 2026-09-08 | Bodenhoff Mads | Option exercise / conversion (M) | Ordinary Shares | 3,000 | USD 110.00 | USD 330,000 | SEC filing ↗ |
| 2026-09-02 | HOLTUG LARS | Sale (S) | Ordinary Shares | 236 | USD 264.13 | USD 62,335 | SEC filing ↗ |
| 2026-08-14 | BIENAIME JEAN JACQUES | Purchase (P) | Ordinary Shares | 2,000 | USD 246.33 | USD 492,654 | SEC filing ↗ |
| 2026-06-02 | SMITH SCOTT THOMAS | Purchase (P) | Ordinary Shares | 100 | USD 219.00 | USD 21,900 | SEC filing ↗ |
| 2026-05-29 | SMITH SCOTT THOMAS | Purchase (P) | Ordinary Shares | 250 | USD 223.32 | USD 55,830 | SEC filing ↗ |
| 2026-05-29 | BIENAIME JEAN JACQUES | Purchase (P) | Ordinary Shares | 500 | USD 223.12 | USD 111,562 | SEC filing ↗ |
| 2026-05-26 | BIENAIME JEAN JACQUES | Purchase (P) | Ordinary Shares | 400 | USD 237.81 | USD 95,122 | SEC filing ↗ |
| 2026-05-11 | JENSEN FLEMMING STEEN | Sale (S) | Ordinary Shares | 19,460 | USD 238.49 | USD 4,641,015 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | ASND |
| CIK | 0001612042 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 13 transaction lines from 2026-05-11 to 2026-09-08 9 P purchase lines · 3 S sale lines · 1 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.